TAZ Is Highly Expressed in Gastric Signet Ring Cell Carcinoma

Table 4

The median overall survival for patients according to TAZ levels.

Characteristics	Number of patients	Median overall survival (months) (95% CI)	𝑃
Age			0.029
<60	61 (41.8%)	16.9 (11.9–22.6)
≥60	85 (58.2%)	12.4 (9.3–14.9)
Sex
Female	35 (24.0%)	14.8 (8.3–21.4)
Male	111 (76.0%)	14.0 (12.6–15.5)
Tumor site			0.312
Distal stomach	49 (33.6%)	14.1 (10.4–17.9)
Proximal stomach	40 (27.3%)	13.7 (12.8–14.6)
Whole stomach	49 (33.6%)	14.1 (9.8–18.3)
Unknown	8 (5.5%)	6.7 (4.8–8.5)
Lymph node			0.294
N0∼1	20 (13.7%)	18.1 (8.7–27.5)
N2∼3	126 (86.3%)	14.0 (12.2–15.8)
Stage			0.029
II	6 (4.1%)	23.25 (10.4–36.1)
III	136 (93.2%)	14.0 (12.4–15.7)
IV	4 (2.7%)	5.1 (4.6–5.6)
Histological grade			0.477
G2	33 (22.6%)	12.9 (10.1–15.7)
G3	113 (77.4%)	14.2 (11.9–16.5)
TAZ protein expression			0.481
Low expression	42 (28.8%)	13.7 (10.9–16.5)
High expression	104 (71.2%)	14.1 (11.4–16.7)
TAZ mRNA expression			0.132
Low expression	29 (35.8%)	8.1 (5.2–10.9)
Intermediate expression	26 (32.1%)	14.0 (12.6–15.5)
High expression	26 (32.1%)	9.6 (6.5–12.6)